Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Depreciation & Amortization (CF): 2016-2024

Historic Depreciation & Amortization (CF) for Mereo BioPharma Group (MREO) over the last 9 years, with Dec 2024 value amounting to $143,000.

  • Mereo BioPharma Group's Depreciation & Amortization (CF) fell 61.00% to $39,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $159,000, marking a year-over-year decrease of 49.04%. This contributed to the annual value of $143,000 for FY2024, which is 28.50% down from last year.
  • According to the latest figures from FY2024, Mereo BioPharma Group's Depreciation & Amortization (CF) is $143,000, which was down 28.50% from $200,000 recorded in FY2023.
  • In the past 5 years, Mereo BioPharma Group's Depreciation & Amortization (CF) ranged from a high of $2.1 million in FY2020 and a low of $143,000 during FY2024.
  • In the last 3 years, Mereo BioPharma Group's Depreciation & Amortization (CF) had a median value of $200,000 in 2023 and averaged $414,247.
  • Per our database at Business Quant, Mereo BioPharma Group's Depreciation & Amortization (CF) increased by 3.97% in 2022 and then tumbled by 77.77% in 2023.
  • Over the past 5 years, Mereo BioPharma Group's Depreciation & Amortization (CF) (Yearly) stood at $2.1 million in 2020, then slumped by 57.85% to $865,423 in 2021, then climbed by 3.97% to $899,742 in 2022, then plummeted by 77.77% to $200,000 in 2023, then decreased by 28.50% to $143,000 in 2024.